The Apolipoprotein A I pipeline drugs market research report outlays comprehensive information on the Apolipoprotein A I targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Apolipoprotein A I pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Cardiovascular, Metabolic Disorders, Genito Urinary System, and Ophthalmology which include the indications Atherosclerosis, Hypercholesterolemia, Lecithin-Cholesterol Acyltransferase (LCAT) Deficiency, Kidney Disease (Nephropathy), and Uveitis. It also reviews key players involved in Apolipoprotein A I targeted therapeutics development with respective active and dormant or discontinued products.
The Apolipoprotein A I pipeline targets constitutes close to five molecules. Out of which, approximately four molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, and Preclinical stages are 1, 1, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Apolipoprotein A I overview
Apolipoprotein AI (Apo-AI) is a protein that in humans is encoded by a gene APOA1. This is a major protein component of high-density lipoprotein (HDL) in plasma. The encoded preproprotein is proteolytically processed to generate the mature protein, which promotes cholesterol efflux from tissues to the liver for excretion and is a cofactor for lecithin cholesterolacyltransferase (LCAT), an enzyme responsible for the formation of most plasma cholesteryl esters. Defects in this gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis.
For a complete picture of Apolipoprotein A I’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.